Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


  
 
  
Reply to this topic

ARX, Aroa Biosurgery Ltd
nipper
post Posted: Jul 26 2020, 02:36 PM
  Quote Post


Posts: 7,306
Thanks: 2512


Listed last week ... up 80% on day One.


Aroa has created a biological scaffold from sheep forestomachs, which is surgically implanted to help patients grow new tissue that has been lost because of disease or injury. It already has a handful of products on the market using its Endoform platform, including scaffolds that can be used to help heal diabetic ulcers, hernias and wounds. The advantage of Aroa's products over other biological scaffolds is that they are substantially cheaper and often also stronger. The scaffolds are made in New Zealand, where sheep are plentiful and they have a unique disease-free status, and exported globally.

The $45 million raised from the listing will go towards financing Aroa's US expansion. With the Capital raise five times oversubscribed, no institution received a full allocation for what they applied. Institutional investors that bought into the IPO include Ellerston Capital, Washington H. Soul Pattinson, Firetrail Investments, Perennial Value Management, OC Funds and Regal Funds Management.

Mr Ward retains the largest shareholding following the listing with 11 per cent of the business, while New Zealand venture capital fund Movac, Movac partners Phil McCaw (who is also a board member) and Richard Abbott, and the Aspire NZ Seed Fund make up the other top five shareholders.
QUOTE
We are very early in the commercialisation of these products, Mr Ward said. Our penetration is still very low and what that means is there's a large opportunity in front of us. "Early on when a product launches, surgeons will evaluate them, but the most important thing is to get good, solid clinical data which gives people confidence in the long-term performance of the product. It's been a significant investment of time and money to develop that data
.
Long-time Aroa chairman Jim McLean said the overriding sentiment when the company listed on Friday was justifiable satisfaction.
QUOTE
What it means for us as much as anything is that this is a financing event, not a liquidity event, and now we're well financed, he said. The biggest advantage of that is being able to attract the best possible people into the business. And the plus for us from COVID is that we're seeing a lot of talented people come back to New Zealand in specialised positions that previously wouldn't have come [back] because their jobs kept them in Australia, Europe or the US.
https://www.afr.com/technology/aroa-surges-...20200724-p55f5a



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jul 16 2020, 12:45 PM
  Quote Post


Posts: 7,306
Thanks: 2512


IPO in August

Highlights

..Aroa Biosurgery is a soft tissue regeneration company whose proprietary Endoform® platform technology is derived from sheep forestomach
..Range of five products that have been used in more than four million procedures to date
..Aroa’s products are covered by a patent portfolio that includes 10 patents and 25 pending patent applications across six patent families
..NZ$22m in product revenue FY20 (ending 31 March 2020) & EBITDA positive
..Clinically proven with peer reviewed publications & regulatory approval in 37 countries
..Existing and new product pipeline focused on US$2.5b total addressable market opportunity in the USA – established distribution with sales in more than 600 hospitals
..Aroa is raising $45m as part of the IPO & will list with an indicative market capitalisation of A$225m under the code ARX. Bell Potter and Wilsons are Joint Lead Managers to the IPO.
..At listing Aroa Founder and CEO Brian Ward will have an 11% shareholding

https://aroabio.com/



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING